Orionis Biosciences
Newton, US · Founded 2015 · Delaware LLC · 5 known investors
Orions Bio discovers, designs and engineers molecules that connect proteins on and within cells to reprogram disease-driving processes or activate immune responses. The company develops small molecule drugs, conditionally active cytokines, and multimodal cell engagers for cancer, autoimmune diseases, and neurodegenerative disorders.
BiotechDeep TechHealthtech
Founders & leadership
NK
Nikolai Kley, Ph.D.Named on SEC filing
NK
Nikolai KleyFounder
Board
GV
Griet Vanpoucke, Ph.D.Board director
SR
Steven R. Gullans, Ph.D.Board director
Investors · 5
Reported raises · per SEC filings
Form D private placements$24.5M disclosed across 3 rounds · 2015–2018
▶$19.7MraisedApr 2018 · 9 investors · BiotechnologyRule 506(b)
▶$19.7MraisedApr 2018 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Griet Vanpoucke, Ph.D.Director
- Nikolai Kley, Ph.D.Executive Officer, Director
- Steven R. Gullans, Ph.D.Director
- Offering amount
- $25.5M
- Amount sold
- $19.7M
- First sale
- Mar 2018
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$750KraisedJan 2017 · 1 investors · BiotechnologyRule 506(b)
▶$750KraisedJan 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nikolai Kley, Ph.D.Executive Officer, Director
- Griet Vanpoucke, Ph.D.Director
- Steven R. Gullans, Ph.D.Director
- Offering amount
- $5.3M
- Amount sold
- $750K
- First sale
- Jan 2017
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$4MraisedOct 2015 · 4 investors · BiotechnologyRule 506(b)
▶$4MraisedOct 2015 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Griet Vanpoucke, Ph.D.Director
- Steven R. Gullans, Ph.D.Director
- Nikolai Kley, Ph.D.Executive Officer, Director
- Offering amount
- $5.3M
- Amount sold
- $4M
- First sale
- Sep 2015
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapAlumis45 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
IQVIA36 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Fortis Life Sciences35 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Companies competing with Orionis Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Orionis Biosciences do?
- Orions Bio discovers, designs and engineers molecules that connect proteins on and within cells to reprogram disease-driving processes or activate immune responses. The company develops small molecule drugs, conditionally active cytokines, and multimodal cell engagers for cancer, autoimmune diseases, and neurodegenerative disorders.
- Who are Orionis Biosciences's investors?
- Orionis Biosciences's investors include Excel Venture Management, Solari Capital, Solasta Ventures, V-Bio Ventures, Wessel Management.
- How much funding has Orionis Biosciences raised?
- Orionis Biosciences has disclosed $24.5M raised across 3 rounds.
- Where is Orionis Biosciences headquartered?
- Orionis Biosciences is headquartered in Newton, US.